Newron is a Swiss Stock Exchange SIX-listed (NWRN) biopharmaceutical company focused on developing novel medicines for diseases of the central nervous system. The company’s marketed product, Xadago (or safinamide), is an add-on therapy to levodopa for the management of Parkinson’s disease, and continues to drive top-line revenues.
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.